CENTAUR is a 24-week, randomized, double-blind, placebo-controlled Phase II clinical trial. The trial’s primary objectives are to evaluate the safety and tolerability of AMX0035 and assess the drug’s impact on disease progression as measured by the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) over the 24-week study period.
This Giving Tuesday, you can directly support Wisconsin Families living with ALS through the programs and services The ALS Association provides, free of charge, in Wisconsin.
Lluvia Alzate started doing pageants in hopes to have the platform needed to spread ALS awareness, while her mom Fanny was battling ALS. Fanny passed away in December 2022, and Lluvia continues to honor her memory. She was crowned Miss Houston USA 2023 and is competing in Miss Texas USA 2023 this summer.
The ALS Association has awarded more than $700,000 to support five promising early career scientists through its Milton Safenowitz Postdoctoral Fellowship Program. This program encourages a pipeline of ALS researchers and innovative ideas that can lead to better ALS treatments and care.
I have a few symptoms that make me worry that I might have ALS. I’ve heard it sometimes takes a long time to know for sure if you have the disease. I think it’s time to see a doctor. Should I go to my general practitioner? And what tests are needed to make the diagnosis?
Last night, WCVB, the Boston ABC affiliate, featured a half-hour show called “Unlocking ALS,” highlighting all the great work coming out of the Boston area in the fight against ALS. The show did a wonderful job covering all the progress that has occurred since the ALS Ice Bucket Challenge (ALS IBC), an organic online movement that catapulted ALS into the spotlight while raising $220 million worldwide.
My mother, Sandra Gaffney, was not your typical person with ALS; living for over 30 years with the disease and remaining furiously independent until the day she died. She really taught me about living life to the fullest and how to cope with challenges.